| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 08/21/2001 | US6277960 Amino acid sequence of g protein coupled receptor; treatment of eating disorders, asthma, parkinson's disease, cardiovascular and nervous system disorders, huntington's disease, tourett's syndrome, and others; diagnosis |
| 08/21/2001 | US6277956 Isolated peptide of defined amino acid sequence which binds to a hla-a2 (human leukocyte antigen-a2) and provokes proliferation of cytolytic t cells; immunology; oncology; vaccines |
| 08/21/2001 | US6277880 Chemical compounds |
| 08/21/2001 | US6277836 Methods and compositions for treating inflammatory bowel disease |
| 08/21/2001 | US6277824 Enhancing or inhibiting cadherin-mediated functions comprising a his-ala-val sequence binding motif, an peptidomimetic or an antibody that binds to such a motif |
| 08/21/2001 | US6277638 Producing nucleic acid fragments or polynucleotides conferring desired phenotype which encodes mutant proteins via repeated cycles of in vitro or in vivo recombination (mutagenesis, shuffling, and selection) |
| 08/21/2001 | US6277635 Use of interleukin-10 to produce a population of suppressor cells |
| 08/21/2001 | US6277633 Lentivirus-based gene transfer vectors |
| 08/21/2001 | US6277631 Recombinant yeast (schizosaccharomyces pombe or saccharomyces cerevisiae) expression vectors |
| 08/21/2001 | US6277621 Artificial chromosome constructs containing foreign nucleic acid sequences |
| 08/21/2001 | US6277620 Polypeptide for the prevention of bacterial infection; bactericides; for vaccine development |
| 08/21/2001 | US6277613 TRF1 binding protein, methods of use thereof |
| 08/21/2001 | US6277599 Monoclonal antiboby for the preferential killing of tumors; for diagnosis of cancer; for the treatment of cancer |
| 08/21/2001 | US6277593 Generating preferential polypeptide; culture transformed cells, express preferential polypeptide, recover preferential polypeptide |
| 08/21/2001 | US6277585 Vertebrate unc-5 proteins which function as receptor proteins for netrins, a family of cell guidance proteins; use in diagnosis, therapy and in the biopharmaceutical industry |
| 08/21/2001 | US6277574 Genes associated with diseases of the kidney |
| 08/21/2001 | US6277561 Isolation and characterization of retrovirus from the hiv group via hybridization of oligonucleotide to nucleic acid indicating the presence of immunodeficiency virus (mvp-5180/91) |
| 08/21/2001 | US6277415 Pediculocidal and veterinary compositions |
| 08/21/2001 | US6277410 Mixture comprises at least one block copolymer with ethylene(oxide) content of 50% or less, and at least one block copolymer with ethylene(oxide) content of 50% or more. |
| 08/21/2001 | US6277383 Ryegrass pollen allergen |
| 08/21/2001 | US6277380 Measles virus mutant antigen |
| 08/21/2001 | US6277373 Phosphatidylinositol 4,5-bisphosphate 5-phosphatase |
| 08/21/2001 | US6277372 Porcine ventral mesencephalic cells obtained from an embryonic pig of between ages 24 and 30 of gestation from embryonic connective tissue; |
| 08/21/2001 | US6277368 Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine |
| 08/21/2001 | CA2288407C Parathyroid hypertensive factor |
| 08/21/2001 | CA2097916C Subunit papillomavirus vaccine and peptides for use therein |
| 08/16/2001 | WO2001059158A1 Compositions and methods for the early diagnosis of ovarian cancer |
| 08/16/2001 | WO2001059130A2 Proteins producing an altered immunogenic response and methods of making and using the same |
| 08/16/2001 | WO2001059123A1 Use of a leptospire protein for preventing and/or diagnosing and/or treating animal and/or human leptospirosis |
| 08/16/2001 | WO2001059110A2 34p3d7: a tissue specific protein highly expressed in prostate cancer |
| 08/16/2001 | WO2001059104A1 Partners of ptb1 domain of fe65, preparation and uses |
| 08/16/2001 | WO2001059093A2 FULL-LENGTH INFECTIOUS cDNA CLONES OF TICK BORNE FLAVIVIRUS |
| 08/16/2001 | WO2001059088A2 Vector |
| 08/16/2001 | WO2001059077A1 Porcine reproductive and respiratory syndrome virus and methods of use |
| 08/16/2001 | WO2001059073A2 Cytotoxic t lymphocytes activated by dendritic cell hybrids |
| 08/16/2001 | WO2001059070A1 Production method of recombinant rotavirus structural proteins and vaccine composition |
| 08/16/2001 | WO2001058957A2 Enhancing the circulating half-life of antibody-based fusion proteins |
| 08/16/2001 | WO2001058956A2 Antibodies that bind human interleukin-18 and methods of making and using |
| 08/16/2001 | WO2001058954A2 Trade molecules and uses related thereto |
| 08/16/2001 | WO2001058951A2 Water-soluble ligand-binding proteins of ligand-gated ion channels, crystals thereof and their use for screening ligands of ligand-gated ion channels |
| 08/16/2001 | WO2001058949A2 Heterologous polypeptide of the tnf family |
| 08/16/2001 | WO2001058947A1 Lipophilin complexes for use in cancer diagnosis and therapy |
| 08/16/2001 | WO2001058945A1 Dna encoding human vanilloid receptor vr3 |
| 08/16/2001 | WO2001058941A1 Cytokine activity regulator molecules from tick salivary glands |
| 08/16/2001 | WO2001058937A2 Interferon-alpha induced genes |
| 08/16/2001 | WO2001058922A2 Method and compositions for treating hepatocellular cancer |
| 08/16/2001 | WO2001058916A2 Antibodies to ccr5 |
| 08/16/2001 | WO2001058915A2 Human g-protein chemokine receptor (ccr5) hdgnr10 |
| 08/16/2001 | WO2001058526A2 Mixtures of caspase inhibitors and complement inhibitors and methods of use thereof |
| 08/16/2001 | WO2001058486A2 Immunomodulatory effective compositions, methods for the production thereof and their use |
| 08/16/2001 | WO2001058484A2 Novel uses of mammalian ccr8 receptors and related reagents |
| 08/16/2001 | WO2001058483A2 METHODS FOR THE PREVENTION AND TREATMENT OF INFECTIONS USING ANTI-C3b(i) ANTIBODIES |
| 08/16/2001 | WO2001058481A2 Diagnostics and therapy of epstein-barr virus in autoimmune disorders |
| 08/16/2001 | WO2001058480A2 Tubulin based vaccine against trypanosomiasis |
| 08/16/2001 | WO2001058479A1 Immunotherapy using interleukin 13 receptor subunit alpha 2 |
| 08/16/2001 | WO2001058477A2 Immunization of an individual against carcinoma and the preliminary stages thereof |
| 08/16/2001 | WO2001058473A1 Method of treating or inhibiting cellular injury or cell death |
| 08/16/2001 | WO2001058472A2 Botulinum toxin pharmaceutical compositions |
| 08/16/2001 | WO2001058469A1 Methods for treating glaucoma |
| 08/16/2001 | WO2001058466A1 Biodegradable and biocompatible polymeric microspheres encapsulating salmonella enteritidisbacteria |
| 08/16/2001 | WO2001058461A1 Mycobacterium ag85 complex-specific t cell peptides and use in diagnostic and therapeutic applications thereof |
| 08/16/2001 | WO2001058446A1 Use of compatible solutes as inhibitors of the enzymatic decomposition of macromolecular biopolymers |
| 08/16/2001 | WO2001027282A8 Plant virus particles with exogenous internal eitopes |
| 08/16/2001 | WO2001024773B1 Liposome-entrapped dna oral vaccines |
| 08/16/2001 | WO2001023550A3 Pca3 messenger rna species in benign and malignant prostate tissues |
| 08/16/2001 | WO2001023416A3 Immunogenic polypeptide derived from moraxella catarrhalis and uses thereof |
| 08/16/2001 | WO2001021192A3 Methods for diagnosis and therapy of hematological and virus-associated malignancies |
| 08/16/2001 | WO2001012172B1 Treatment of metastatic disease |
| 08/16/2001 | WO2001010893A3 Il-16 antagonists |
| 08/16/2001 | WO2001010413A3 Periodic structures comprising lipids, polyelectrolytes, and structures-inducing soluble oligovalent linkers |
| 08/16/2001 | WO2001009303A3 Flt-3 LIGAND-ENCODING POLYNUCLEOTIDE AS A POLYNUCLEOTIDE-BASED VACCINE ENHANCER |
| 08/16/2001 | WO2001009293A3 Mammalian adhesion protease peptides |
| 08/16/2001 | WO2001009173A3 Use of quinic, shikimic acids and their derivatives for preparing mannose receptor ligands |
| 08/16/2001 | WO2001009172A3 Immunogenic polypeptide derived from moraxella catarrhalis and uses thereof |
| 08/16/2001 | WO2001007595A3 Novel fibroblast growth factor and nucleic acids encoding same |
| 08/16/2001 | WO2001006989A3 Methods and compositions for inhibiting polypeptide accumulation associated with neurological disorders |
| 08/16/2001 | WO2000058506A3 Susceptibility to psoriasis |
| 08/16/2001 | WO2000006739A3 Chlamydia antigens and corresponding dna fragments and uses thereof |
| 08/16/2001 | WO1999064046A8 Multivalent agonists, partial agonists, inverse agonists and antagonists of the 5-ht3 receptors |
| 08/16/2001 | US20010014734 Controllers |
| 08/16/2001 | US20010014673 Genetic engineering |
| 08/16/2001 | US20010014672 High molecular weight major outer membrane protein of moraxella |
| 08/16/2001 | US20010014668 Colonization factor antigens; epitopes; immunization against diarrheagenic Escherichia |
| 08/16/2001 | US20010014649 Chromatography adsorbents utilizing mercapto heterocyclic ligands |
| 08/16/2001 | US20010014474 Preparing hybridoma cell line which produces antibody which specifically recognizes and binds to cell surface antigen associated with a neoplastic human cell; diagnosis, therapy |
| 08/16/2001 | US20010014470 Polypeptide having antigenic determinant identical to antigenic determinant of a protein produced by cells infected with simian T-lymphotrophic virus or HTLV-IV, the protein selected from cell-surface glycoproteins, gag proteins |
| 08/16/2001 | US20010014464 Nucleic acid encoding follistatin-3 |
| 08/16/2001 | US20010014447 Methods for the detection of encysted parasites |
| 08/16/2001 | US20010014337 A peptide having substantial homology with the CBF1/RBPJk (cell binding factor-1/recombination bining protein J kappa) interaction domain of EBNA2 comprising specific peptide containing 15-20 amino acids |
| 08/16/2001 | US20010014336 Administering to the warm blooded animal for treating parasitic, bacterial and viral diseases a non-aqueous macrolide compound selected from avermectins and mibemycins |
| 08/16/2001 | US20010014335 A fusion protein comprising a polypeptide having antigenicity of Mycoplasma gallisepticum and a polypeptide derived from herpesvirus outer membrane protein being ligated with polypeptide having antigenicity of mycoplasma at N-terminum |
| 08/16/2001 | US20010014334 Methods and materials for the treatment of prostatic carcinoma |
| 08/16/2001 | US20010014331 Vaccine comprising a low dose of each of diphtheria toxoid (D), tetanus toxoid (T), pertussis toxin (PT), filamentous hemagglutinin (FHA) and pertactin (69K), vaccine maintains an ability to prevent pertussis while showing low reactogenicity |
| 08/16/2001 | US20010014330 Immunization against endogenous molecules |
| 08/16/2001 | US20010014328 A multispecific binding molecule, comprising a first binding determinant which binds an Fc alpha receptor is not blocked by human immunoglobin A and a second binding determinant binds target cancer cell antigen |
| 08/16/2001 | US20010014327 Conjugate molecules are produced by genetic modification of genes encoding light and heavy chains of the surface structure specific antibody and expression in mammal cells to produce the conjugated antibody; enhanced immune response |
| 08/16/2001 | US20010014326 Protein formulation |
| 08/16/2001 | US20010014325 Monoclonal antibodies against leukocyte adhesion receptor beta-chain, methods of producing these antibodies and use therefore |
| 08/16/2001 | EP1144678A3 Susceptibility to psoriasis |
| 08/16/2001 | EP1123711A1 Vaccine preparations containing attenuated toxin |